HUTCHMED’s Savolitinib Combo Extends Survival in Lung Cancer, Boosting Global Ambitions
TREE NEWS reports: HUTCHMED (China) Limited announced on October 26 that its global Phase III SAFFRON trial of savolitinib combined with AstraZeneca’s osimertinib met its primary endpoint, significantly improving outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who progressed on osimertinib and harbor MET overexpression/amplification. The combination reduced the risk of death by 32% compared to platinum-based chemotherapy, with median overall survival (OS) extending from 12.9 to 17.8 months—a gain of nearly 5 months. The results were presented at the ESMO 2026 Presidential Symposium in Madrid and simultaneously published in the New England Journal of Medicine.
Market Implications
The positive data could reinvigorate investor interest in HUTCHMED, which has seen its shares under pressure amid a broader biotech downturn. Savolitinib, partnered with AstraZeneca since 2011, is a key asset in HUTCHMED’s portfolio. AstraZeneca handles global commercialization outside China, with HUTCHMED eligible for tiered royalties of 9-13% on ex-China sales plus milestone payments. A successful global launch could provide a steady revenue stream and validate HUTCHMED’s R&D capabilities.
Beyond the resistant setting, the China-only SANOVO trial showed a median progression-free survival (PFS) of 24.9 months for the combo versus 13.8 months for osimertinib alone in first-line EGFR-mutant NSCLC with MET overexpression, with a median OS of 44.5 vs 34.9 months. Although OS statistical significance was not confirmed, the data support expanding the label into first-line treatment, potentially broadening the addressable population. HUTCHMED plans to submit a supplemental New Drug Application in China by end-2026.
Regulatory submissions for the resistant setting are already under review by the US FDA, EMA, and Japan’s PMDA. Approval in these markets would mark HUTCHMED’s second global oncology product after fruquintinib, which is commercialized by Takeda outside China. However, investors should note that clinical success does not guarantee commercial success; pricing, reimbursement, competition, and MET testing adoption will determine the drug’s peak sales.
For AstraZeneca, the combo offers a lifecycle extension for its blockbuster osimertinib franchise, potentially staving off competition from newer therapies. The data may also bolster AstraZeneca’s oncology portfolio and support its growth outlook.
Key Takeaways
- SAFFRON trial met primary endpoint with a 32% reduction in risk of death and a 4.9-month OS benefit, supporting regulatory filings in the US, Europe, and Japan.
- First-line SANOVO data showed a 11.1-month PFS improvement, paving the way for a label expansion in China by 2026.
- HUTCHMED stands to gain royalties and milestones, but commercialization risks and competition remain.
- AstraZeneca benefits from extended osimertinib franchise and strengthened oncology portfolio.
- Investors should watch regulatory decisions and MET testing adoption as key catalysts.
